Stock research
ENTX Entera Bio Ltd.
Healthcare • Biotechnology
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack...…
Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.
1Y change
+53.33%
Range high
$3.92
Congress · 90d
0
Insiders · 90d
0
Public signal layer
Who is disclosing activity in ENTX?
Price
Showing 1Y history. Source: FMP historical price full.
- Prev Close
- $2.95
- Day High
- $3.20
- Day Low
- $2.92
- 52w High
- $4.20
- 52w Low
- $0.91
- Volume
- 1,040,297
- Avg Volume
- Beta
- 1.433
* TTM/most recent where available
Company
- Ticker
- ENTX
- Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- IL
- CEO
- Miranda J. Toledano
- Employees
- 22
- Website
- www.enterabio.com
Key Metrics
- Market Cap
- 147M
- P/E
- P/B
- P/S
- EV/EBITDA
- ROE
- Net Margin
- Div Yield
- FCF/Share
* TTM/most recent where available
DCF Valuation
Standard DCF
Levered DCF
Market Price
DCF vs Price (30D window)
Price uses last 30 days; DCF line holds latest value across the window.DCF line = solid green (latest value repeated across window), Price = dashed blue (daily closes).